Bacterial β-glucuronidases expressed by the symbiotic intestinal microbiota appear to play important roles in drug-induced epithelial cell toxicity in the gastrointestinal (GI) tract. For the anticancer drug CPT-11 (Irinotecan) and the non-steroidal anti-inflammatory drug diclofenac, it has been shown that removal of the glucuronide moieties from drug metabolites by bacterial β-glucuronidases in the GI lumen can significantly damage the intestinal epithelium.
Mol #85852
Introduction CPT-11 (Irinotecan, (1-piperidino)-1-piperidino]) is employed worldwide for the treatment of a variety of solid malignancies, but its efficacy is often limited by severe GI toxicity (Rothenberg et al., 1996; Rougier et al., 1997; Cunningham et al., 1998; Rougier et al., 1998; Saltz et al., 2000; Fuchs et al., 2003; Hu et al., 2006; Kurita et al., 2011) . CPT-11 is most frequently utilized in first-and second-line treatment of metastatic colon cancers, typically in combination with other agents (Smith et al., 2006; Kambe et al., 2012) . More recently, has been employed in preclinical and clinical trials against a range of other neoplasticities, including brain tumors, lung, breast, gastric, pancreatic, and gynecological cancers (Matsumura et al., 2010; Han et al., 2012; Jo et al., 2012; Kim et al., 2012; Spigel et al., 2012; Zaniboni et al., 2012; Lee et al., 2013) .
CPT-11 is a prodrug that is converted to SN-38 (7-Ethyl-10-hydroxy-camptothecin) by carboxylesterase (CE) enzymes. SN-38, the active metabolite of CPT-11, induces anti-tumor effects by poisoning the human topoisomerase I catalytic cycle, leading to cell death (Kawato et al., 1991; Mathijssen et al., 2001; Ma and McLeod, 2003) . The fate of SN-38 in vivo is further regulated by UDP-glucuronosyltransferase (UGT) enzymes in the liver and other tissues. UGT isoforms, in particular UGT1A1, catalyze the conjugation of a glucuronide group onto SN-38, producing the inactive compound SN-38 glucuronide (SN-38G), which is marked for elimination through the bile and into the GI tract (Nagar and Blanchard, 2006) . However, as passes through the GI tract, it acts as a substrate for bacterial β -glucuronidases present in intestinal symbiotic microbes (Tobin et al., 2003; Stein et al., 2010) . These enzymes, in turn, reactivate SN-38 in situ, resulting in toxic injury to the intestinal epithelial cells (Araki et al., 1993) . Indeed, the severity of CPT-11-induced diarrhea is correlated with levels of β -Mol #85852 glucuronidase activity in the intestinal lumen, and the intestinal microbiota have been found to play an important role in the development of this toxicity (Takasuna et al., 1996; Takasuna et al., 1998; Mathijssen et al., 2001; Brandi et al., 2006) . While most early-onset diarrhea associated with CPT-11 treatment can be treated with anti-motility agents, the delayed GI toxicity associated with SN-38 can be refractory to standard treatments (Saliba et al., 1998) . It has now been convincingly demonstrated that the intestinal toxicity of CPT-11 limits dose intensification and optimized delivery of CPT-11 (Abigerges et al., 1994; Ducreux et al., 2003; Zhao et al., 2004 ).
The role microbial enzymes expressed by symbiotic bacteria play in therapeutic metabolism has been appreciated since the early days of drug discovery (Sousa et al., 2008) .
We recently hypothesized that selective microbial β -glucuronidase inhibitors would alleviate CPT-11-induced toxicity. In vitro and cell-based assays demonstrated that a set of chemically similar compounds identified by high-throughput screening displayed potent inhibition of E. coli β -glucuronidase and did not impact the viability of cultured bacterial or mammalian cells (Wallace et al., 2010) . Crystal structures of inhibitors in complex with E. coli β -glucuronidase reveal that the small molecules bind to a loop present in bacterial β-glucuronidases but missing in the mammalian orthologs; accordingly, the inhibitors examined had no inhibitory effect in vitro on a mammalian β -glucuronidase (Wallace et al., 2010) . Oral administration of one of the inhibitors to mice alleviated CPT-11-induced diarrhea and intestinal damage (Wallace et al., 2010) . Furthermore, in a subsequent study, the administration of the same inhibitor protected mice from small intestinal ulceration caused by the non-steroidal anti-inflammatory drug diclofenac, which is also subject to glucuronidation and reactivation in the intestinal lumen (LoGuidice et al., 2012 ).
Here we describe the inhibitory profile of four novel inhibitors that are chemically distinct from the originally reported set (Wallace et al., 2010; Ahmad et al., 2011) . These compounds are shown to be in vitro inhibitors of E. coli β -glucuronidase but are non-lethal to cultured E. coli Mol #85852 6 and mammalian cells. The x-ray crystal structure of E. coli β -glucuronidase in complex with one of the inhibitors reveals that it binds to the entrance of the enzyme's active site and makes contact with, but does not completely order, the flexible "bacterial loop" unique to the microbial β -glucuronidases. We also show that the most potent of these new compounds protects mice from CPT-11-induced diarrhea. Taken together, these data enhance our understanding of the selective modulation of microbial β -glucuronidases, which may lead to the targeted alleviation of drug-induced toxicity in the human GI tract.
Materials and Methods
Expression and Purification of E. coli β -Glucuronidase. E coli β -glucuronidase (EC 3.2.1.31) was expressed and purified as described previously (Wallace et al., 2010) . Purified E coli β -glucuronidase was stored in 20 mM HEPES, 50 mM NaCl, pH 7.4 at ~10 mg/mL at -80 o C.
The Δ360-376 form of E. coli β -glucuronidase was created using PCR mutagenesis, confirmed by sequencing, and purified as described previously (Wallace et al., 2010) .
Inhibitor Compounds. Compounds (Figure 1 ) identified from high-throughput screening (Wallace et al., 2010; Ahmad et al., 2011) were purchased from ASINEX, Inc, Moscow, Russia.
Each compound was provided as a solid powder and dissolved initially in 100% DMSO at 25 mM. (Graef et al., 1977) . Each of the four inhibitors was tested for an effect on each glycosidase enzyme activity by adding a concentration range of 0 to 100 µM to the reaction mixture. The reaction was allowed to proceed for 6 hours at 37 o C and then quenched with 100 µL 0.2 M sodium carbonate. Absorbance was measured at the appropriate wavelength, and the data were analyzed using Microsoft Excel and SigmaPlot 11.0. once daily in the morning, and Inhibitor 5 gavaged (10 µg/day) twice per day (every 10 hours).
Kinetic and Equilibrium Inhibition

Toxicity of Inhibitors toward
Total injected volume was identical for each animal. Mice were weighed and examined daily for signs of diarrhea (fecal staining of skin, lose watery stool) and bloody diarrhea (black sticky stool). Body weight, stool consistency and blood in stool were monitored daily using methods previously published (Cooper et al., 1993; Wallace et al., 2010) . Previous studies indicate that dosing at ~60-80 mg/kg/day of CPT-11 for 4 days allows for observation of delayed diarrhea around 15 days (Reagan-Shaw et al., 2008) . A dosing scheme of 50 mg/kg/day, once daily for 9 days, was chosen with the intention of accelerating the onset of diarrhea while preventing death.
As outlined previously, 50 mg/kg CPT-11 in mice is roughly equivalent to the 5 mg/kg typical human CPT-11 dose based on differences in body surface area (BSA) (Brandi et al., 2006; Reagan-Shaw et al., 2008) . GI symptoms in Group 3 started as early as day 2 and up to day 10, and included decreased appetite, bowel movements, mobility and body weight. All animals were euthanized on day 11.
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Results
In Vitro and Cell-Based E. coli β
-Glucuronidase Inhibition
Four compounds were chosen from high-throughput screening results (Wallace et al., 2010; Ahmad et al., 2011) for further functional and structural characterization (Figure 1 ).
These compounds (Inhibitors 5-8) are relatively distinct in structure from one another, and are also distinct from the four chemically-similar compounds (Inhibitors 1-4) reported previously (Wallace et al., 2010 
Selectivity for Bacterial
β -Glucuronidase
We next tested the ability of Inhibitors 5-8 to disrupt the activity of β -glucuronidase from bovine liver, a mammalian enzyme ortholog that processes larger glucosaminoglycan substrates relative to the bacterial β -glucuronidases (Ray et al., 1999) . We found that Inhibitors 
Lethality to Bacterial or Mammalian Cells
Eliminating toxic drug metabolites in the GI tract by disrupting microbial β -glucuronidases requires that inhibitors are not harmful to human or bacterial cells. Indeed, it is increasingly well established that symbiotic microbiota are essential for GI health (Consortium, 2012) . We tested whether Inhibitors 5-8 were lethal to cultured E. coli cells or HCT116 human colon cancer cells at compound concentrations up to 100 μM. We found that all four inhibitors did not affect the survival of either E. coli or HCT116 cells (Figure 3 ). Thus, they appear to satisfy the criteria that successful compounds are relatively non-toxic to bacterial cells or human epithelial cells.
Structure of E. coli β -Glucuronidase Complexed with Inhibitor 8
To further our understanding of the molecular basis of E. coli The full "bacterial loop" of E. coli β -glucuronidase, residues 360-376, was visualized in the Inhibitor 2 and 3 co-crystal structures (Wallace et al., 2010) ; in complex with Inhibitor 8, though, only residues 372-376 are ordered with average B-factors less than 80 Å 2 ( Figure 6A ).
In the absence of a bound ligand, the "bacterial loop" is not observed, as it gave no interpretable electron density in the structure of apo E. coli β -glucuronidase reported previously (Wallace et al., 2010 
Alleviation of CPT-11 Toxicity in Mice
Lastly, we tested the ability of the most potent compound examined in this study, Inhibitor 5 (K i =180 nM, EC 50 =300 nM), to alleviate CPT-11-induced intestinal toxicity in mice.
We divided BALB/cJ female mice into four groups of nine animals each. The mice were observed and weighed daily, and were examined for incidence of diarrhea ( Figure 7) . Groups 1 and 2 showed no evidence of toxicity throughout the experiment. In group 3, GI symptoms were observed as early as day 2 and incidences of bloody diarrhea were observed in a third of the mice at day 8, and in all animals by day 10. In comparison, in group 4, where the mice were pretreated with Inhibitor 5, no mice showed evidence of bloody diarrhea by day 8 and less than 30% of mice showed symptoms by day 10 ( Figure 7A ).
The body weight of each mouse was also recorded each day during the course of the experiment ( Figure 7B ). Although Inhibitor 5 alleviated most of the toxicity associated with the CPT-11 treatment, it had no effect on the average body weight of the mice. Moreover, group 2, which only received treatment with Inhibitor 5, showed comparable body weights to the vehicleonly group, but had significantly higher body weights, starting at day 6, than group 4, which received treatment with Inhibitor 5 in addition to CPT-11. These data indicate that the presence of Inhibitor 5 significantly reduces the incidence of acute GI toxicity caused by CPT-11, and they suggest that Inhibitor 5 does not impact the systemic effects of this anticancer drug, as measured by weight loss.
Discussion
Research endeavors like the Human Microbiome Project continue to expand our appreciation of the roles the symbiotic microbiota play in mammalian physiology (Consortium, 2012) . It also appears that widespread use of antibiotics may have subtle but serious side effects on human health (Maurice et al., 2013) . Additionally, for patients with colorectal cancer, the use of antibiotics to treat CPT-11-induced toxicity may lead to the increased prevalence of subdominant bacterial species with higher overall β -glucuronidase activity in the GI tract, and thus, increased toxicity (Brandi et al., 2006) . Studies have also shown that the long-term use of neomycin in mice leads to increased serum bilirubin that may interfere with proper hepatic CPT-11 metabolism (Vítek et al., 2005) . These observations lead to the conclusion that the selective, through the reactivation of SN-38G to SN-38 in the tumor microenvironment (Tobin et al., 2006; Huang et al., 2011) . Of the four compounds described here, only Inhibitor 5 (K i and IC 50 values of 180 and 540 nM, respectively) displayed potency comparable to our previously-characterized inhibitors, which have a scaffold not shared by the four inhibitors outlined in this study (Wallace et al., 2010) . As such, these data advance our understanding of the chemical moieties capable of selective bacterial β -glucuronidase inhibition.
We successfully determined the x-ray crystal structure of one of our inhibitors (Inhibitor Lastly, only the previously reported Inhibitor 1 had been examined to date in druginduced GI toxicity studies in mice (Wallace et al., 2010; LoGuidice et al., 2012) . In this report, we tested the in vivo efficacy our most effective compound outlined here, Inhibitor 5, in a mouse model of CPT-11 toxicity ( Figure 7 ). Groups of BALB/cJ mice were dosed with Inhibitor 5, CPT-11, or a combination of both. The group that received CPT-11 alone developed bloody diarrhea by day 8, and 100% of the mice showed signs of this toxicity by day 10. The group that was treated with Inhibitor 5 orally, along with CPT-11 by i.p., had significantly fewer incidents of bloody diarrhea compared to the CPT-11 group, highlighting the protective effects of Inhibitor 5.
It is also interesting to note that the mice that received CPT-11 lost body weight at the same rate regardless of treatment with Inhibitor 5. This suggests that Inhibitor 5 protected against CPT-11-induced GI toxicity but that the systemic pharmacodynamics of CPT-11 in the mouse are not impacted. A more comprehensive examination of tumor xenografts and pharmacokinetics will be required to substantiate this conclusion.
We have described the inhibitory profile of a range of chemically-distinct compounds and assessed their potential as orally delivered pharmacological agents. They are in vitro inhibitors to E. coli β -glucuronidase and, with the exception of Inhibitor 7, are also effective in E. coli cells.
Moreover, our inhibitors appear to be selective for bacterial β -glucuronidase and non-lethal to bacterial and mammalian cells. The structural data presented here, along with the data from our previously-characterized inhibitors, will allow us to better understand their mechanism of selective microbial β -glucuronidase inhibition. As such, they may facilitate the development of This article has not been copyedited and formatted. The final version may differ from this version. Inhibitor 2 (yellow) from a previously resolved structure is also shown, as are the side chains for the Inhibitor 8 and Inhibitor 2 complexes (blue and purple, respectively). Table 2 This article has not been copyedited and formatted. The final version may differ from this version. 
